Effect of genetic variation in STXBP5 and STX2 on von willebrand factor and bleeding phenotype in type 1 von willebrand disease patients

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  van Loon, Janine E ^a   Sanders, Yvonne V ^a   de Wee, Eva M ^a   Kruip, Marieke J H A ^a   de Maat, Moniek P M ^a   Leebeek, Frank W G ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

SYNTAXIN 2; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLEEDING; DISEASE SEVERITY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; MOLECULAR PHYLOGENY; PATIENT ASSESSMENT; PHENOTYPE; PRACTICE GUIDELINE; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; SYNTAXIN 2 GENE; SYNTAXIN BINDING PROTEIN 5 GENE; VON WILLEBRAND DISEASE;

ADULT; FEMALE; HAPLOTYPES; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; R-SNARE PROTEINS; SYNTAXIN 1; VON WILLEBRAND DISEASE, TYPE 1; VON WILLEBRAND FACTOR; YOUNG ADULT;

EID: 84863636752     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040624     Document Type: Article

References (14)

1. Ruggeri ZM, (2000) Old concepts and new developments in the study of platelet aggregation. J Clin Invest 105: 699-701.
2. Ruggeri ZM, Ware J, (1993) von Willebrand factor. Faseb J 7: 308-316.
3. Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, et al. (2006) Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 4: 2103-2114.
4. Smith NL, Chen MH, Dehghan A, Strachan DP, Basu S, et al. (2010) Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation 121: 1382-1392.
5. Widberg CH, Bryant NJ, Girotti M, Rea S, James DE, (2003) Tomosyn interacts with the t-SNAREs syntaxin4 and SNAP23 and plays a role in insulin-stimulated GLUT4 translocation. J Biol Chem 278: 35093-35101.
6. Lowenstein CJ, Morrell CN, Yamakuchi M, (2005) Regulation of Weibel-Palade body exocytosis. Trends Cardiovasc Med 15: 302-308.
7. van Loon JE, Leebeek FW, Deckers JW, Dippel DW, Poldermans D, et al. (2010) Effect of genetic variations in syntaxin-binding protein-5 and syntaxin-2 on von Willebrand factor concentration and cardiovascular risk. Circ Cardiovasc Genet 3: 507-512.
8. Macfarlane DE, Stibbe J, Kirby EP, Zucker MB, Grant RA, et al. (1975) Letter: A method for assaying von Willebrand factor (ristocetin cofactor). Thromb Diath Haemorrh 34: 306-308.
9. Tosetto A, Rodeghiero F, Castaman G, Bernardi M, Bertoncello K, et al. (2007) Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1VWD). J Thromb Haemost 5: 715-721.
10. Gallinaro L, Cattini MG, Sztukowska M, Padrini R, Sartorello F, et al. (2008) A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood 111: 3540-3545.
11. Sadler JE, (2009) Low von Willebrand factor: sometimes a risk factor and sometimes a disease. Hematology Am Soc Hematol Educ Program pp. 106-112.
12. Cumming A, Grundy P, Keeney S, Lester W, Enayat S, et al. (2006) An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease. Thromb Haemost 96: 630-641.
13. Goodeve A, Eikenboom J, Castaman G, Rodeghiero F, Federici AB, et al. (2007) Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood 109: 112-121.
14. James PD, Notley C, Hegadorn C, Leggo J, Tuttle A, et al. (2007) The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study. Blood 109: 145-154.